Anupam Rasayan India Limited – Investor Presentation Summary

Key Operational Highlights

  • Bliss GVS Pharma manufactures branded formulations across Anti-malarial, Anti-fungal, Antibacterial, Antibiotic, anti-inflammatory, Anti-infective, Anti-diabetic, Cardiovascular, Gastrointestinal, Respiratory, Urology and contraceptive segments
  • Company has 6 Manufacturing facilities in Palghar, Vevoor and Ambernath across Maharashtra
  • Current capacity utilization is only 30% with significant headroom available for improvement
  • Robust pipeline of 62+ molecules, with 48+ molecules catering to regulated markets
  • First EU-GMP certified suppositories manufacturer in India
  • Global accreditations include US FDA, EU GMP, FDA Russia, Health Canada, WHO GMP, TGA Australia and 25+ other accreditations

Key drivers of operational performance:

  • Long-standing distributor relationships spanning over 20-25 years
  • Signed Strategic agreements in USA and Canada
  • Received US FDA approval for Palghar suppository unit
  • Expansion into regulated markets through Vevoor facility

Strategic & R&D Initiatives

  • Expansion into Cardiovascular, Antidiabetic, Antibiotics, Analgesic & Anti-inflammatory, Anti-Retrovirals, Antifungals, Anti-depressant and Antimalarial segments
  • Forward Integration: End-to-End Vertically integrated Manufacturing to give cost and resource leverage
  • Expanding USA Footprint: Leveraging expertise of Anupam in North America and European markets
  • Expansion into CDMO Business

Transaction Details

  • Acquisition of 43.3-48.2%+ controlling stake through open offer to public shareholders
  • Source of Funds: Term Loan of ~Rs 300 Crores & Non-Controlling Non-voting equity instrument for balance amount
  • Investor Relations Advisor: Strategic Growth Advisors Pvt. Ltd.